- Home
- BRW vs AUTL Comparison
BRW vs AUTL Comparison
Compare BRW & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BRW | AUTL |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 340.0M | 385.9M |
| IPO Year | 1996 | 2025 |
Fundamental Metrics
Financial Performance| Metric | BRW | AUTL |
|---|---|---|
| Price | $6.67 | $1.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 230.8K | ★ 1.1M |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,120,000.00 |
| Revenue This Year | N/A | $80.32 |
| Revenue Next Year | N/A | $53.96 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $6.38 | $1.18 |
| 52 Week High | $8.49 | $2.70 |
Technical Indicators
Market Signals| Indicator | BRW | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 49.52 | 42.97 |
| Support Level | $6.42 | $1.37 |
| Resistance Level | $6.93 | $1.52 |
| Average True Range (ATR) | 0.07 | 0.10 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 44.68 | 20.55 |
Price Performance
Historical ComparisonAbout BRW Saba Capital Income & Opportunities Fund SBI
Saba Capital Income & Opportunities Fund is a diversified, closed-end management investment company. It seeks to provide investors with a high level of current income, with a secondary goal of capital appreciation. It invests globally in debt and equity securities of public and private companies, which includes, investing in closed-end funds, public and private debt instruments, and other securities.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.